JP2020518651A - 抗血管新生ペプチドの持続送達のための生分解性微粒子 - Google Patents
抗血管新生ペプチドの持続送達のための生分解性微粒子 Download PDFInfo
- Publication number
- JP2020518651A JP2020518651A JP2019561277A JP2019561277A JP2020518651A JP 2020518651 A JP2020518651 A JP 2020518651A JP 2019561277 A JP2019561277 A JP 2019561277A JP 2019561277 A JP2019561277 A JP 2019561277A JP 2020518651 A JP2020518651 A JP 2020518651A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- abu
- microparticles
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 136
- 239000011859 microparticle Substances 0.000 title claims abstract description 117
- 230000001772 anti-angiogenic effect Effects 0.000 title claims abstract description 17
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 34
- 230000002459 sustained effect Effects 0.000 title description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 72
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims abstract description 58
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 36
- 239000004310 lactic acid Substances 0.000 claims abstract description 36
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 24
- 208000002780 macular degeneration Diseases 0.000 claims abstract description 21
- 108010042086 Collagen Type IV Proteins 0.000 claims abstract description 5
- 102000004266 Collagen Type IV Human genes 0.000 claims abstract description 5
- 239000000835 fiber Substances 0.000 claims abstract 2
- 150000001413 amino acids Chemical class 0.000 claims description 39
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 21
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 12
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 12
- 238000002560 therapeutic procedure Methods 0.000 claims description 10
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 7
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 208000004644 retinal vein occlusion Diseases 0.000 claims description 6
- 208000001344 Macular Edema Diseases 0.000 claims description 4
- 206010025415 Macular oedema Diseases 0.000 claims description 4
- 201000010230 macular retinal edema Diseases 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims description 3
- 201000011190 diabetic macular edema Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 239000010419 fine particle Substances 0.000 claims 9
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims 2
- 238000013268 sustained release Methods 0.000 abstract description 6
- 239000012730 sustained-release form Substances 0.000 abstract description 6
- 238000010586 diagram Methods 0.000 abstract description 4
- 108700001716 AXT107 Proteins 0.000 description 41
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 26
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 26
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 18
- 239000002245 particle Substances 0.000 description 18
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 229920001577 copolymer Polymers 0.000 description 10
- 229940090044 injection Drugs 0.000 description 10
- 108010081667 aflibercept Proteins 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000002792 vascular Effects 0.000 description 9
- 229960002833 aflibercept Drugs 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- 230000007704 transition Effects 0.000 description 8
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 4
- 206010029113 Neovascularisation Diseases 0.000 description 4
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 4
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 4
- 102000004584 Somatomedin Receptors Human genes 0.000 description 4
- 108010017622 Somatomedin Receptors Proteins 0.000 description 4
- 108091008605 VEGF receptors Proteins 0.000 description 4
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 150000008575 L-amino acids Chemical class 0.000 description 3
- 229920001400 block copolymer Polymers 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000009261 transgenic effect Effects 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229940027545 aflibercept injection Drugs 0.000 description 2
- WNNNWFKQCKFSDK-UHFFFAOYSA-N allylglycine Chemical compound OC(=O)C(N)CC=C WNNNWFKQCKFSDK-UHFFFAOYSA-N 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011221 initial treatment Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000012753 TIE-2 Receptor Human genes 0.000 description 1
- 108010090091 TIE-2 Receptor Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000011325 dry age related macular degeneration Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940051306 eylea Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502913P | 2017-05-08 | 2017-05-08 | |
| US62/502,913 | 2017-05-08 | ||
| PCT/US2018/031663 WO2018208829A1 (en) | 2017-05-08 | 2018-05-08 | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518651A true JP2020518651A (ja) | 2020-06-25 |
| JP2020518651A5 JP2020518651A5 (enExample) | 2021-07-26 |
Family
ID=64104968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561277A Withdrawn JP2020518651A (ja) | 2017-05-08 | 2018-05-08 | 抗血管新生ペプチドの持続送達のための生分解性微粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200179285A1 (enExample) |
| EP (1) | EP3621597A4 (enExample) |
| JP (1) | JP2020518651A (enExample) |
| KR (1) | KR20200003859A (enExample) |
| CN (1) | CN111315364A (enExample) |
| AU (1) | AU2018266690A1 (enExample) |
| CA (1) | CA3063140A1 (enExample) |
| WO (1) | WO2018208829A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ771201A (en) | 2017-04-06 | 2025-01-31 | Sustain Holdings Llc | Collagen Peptide-Based Medicament Compositions And Devices And Methods Of Production And Use Thereof |
| EP3661536A4 (en) | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR |
| KR20210146352A (ko) * | 2019-03-26 | 2021-12-03 | 아스클리픽스 테라퓨틱스, 인크. | 안구 질환 치료용 조성물 및 방법 |
| PT3958889T (pt) | 2019-04-22 | 2025-04-10 | Sustain Holdings Llc | Composições de péptidos miméticos de colagénio para o tratamento de uma doença ou perturbação ocular so segmento posterior que envolve a retina, os vasos sanguíneos da retina, os nervos retinianos ou o nervo ótico |
| IT202100023357A1 (it) | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptidi con attività anti-angiogenica |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717694B2 (en) * | 2009-05-15 | 2017-08-01 | The Johns Hopkins University | Peptide/particle delivery systems |
| US10314917B2 (en) * | 2013-03-15 | 2019-06-11 | The Brigham And Women's Hospital, Inc. | Targeted polymeric inflammation-resolving nanoparticles |
| DK3003343T3 (da) * | 2013-06-07 | 2020-02-03 | Univ Johns Hopkins | Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme |
| JP2019535651A (ja) * | 2016-10-04 | 2019-12-12 | アスクレピクス セラピューティクス インコーポレイテッド | Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法 |
-
2018
- 2018-05-08 WO PCT/US2018/031663 patent/WO2018208829A1/en not_active Ceased
- 2018-05-08 KR KR1020197035367A patent/KR20200003859A/ko not_active Ceased
- 2018-05-08 CA CA3063140A patent/CA3063140A1/en not_active Abandoned
- 2018-05-08 AU AU2018266690A patent/AU2018266690A1/en not_active Abandoned
- 2018-05-08 CN CN201880039876.3A patent/CN111315364A/zh active Pending
- 2018-05-08 EP EP18797771.5A patent/EP3621597A4/en not_active Withdrawn
- 2018-05-08 JP JP2019561277A patent/JP2020518651A/ja not_active Withdrawn
- 2018-05-08 US US16/612,124 patent/US20200179285A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018208829A1 (en) | 2018-11-15 |
| EP3621597A1 (en) | 2020-03-18 |
| AU2018266690A1 (en) | 2019-12-12 |
| KR20200003859A (ko) | 2020-01-10 |
| US20200179285A1 (en) | 2020-06-11 |
| WO2018208829A8 (en) | 2019-07-04 |
| CN111315364A (zh) | 2020-06-19 |
| CA3063140A1 (en) | 2018-11-15 |
| EP3621597A4 (en) | 2021-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518651A (ja) | 抗血管新生ペプチドの持続送達のための生分解性微粒子 | |
| US7531173B2 (en) | Ophthalmic composition of a VEGF antagonist | |
| JP2025131583A (ja) | 治療用又は診断用薬剤を含む粒子並びにその懸濁液及び使用方法 | |
| CA2846209C (en) | Systemic sustained release formulation comprising elastinlike peptide repeating sequence and protein active agent | |
| US9044436B2 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| Lin et al. | Nanotechnology-based drug delivery treatments and specific targeting therapy for age-related macular degeneration | |
| JP2018515582A (ja) | 眼の障害の処置のためのカプセル化細胞療法の使用 | |
| JP2020518651A5 (enExample) | ||
| KR20110070850A (ko) | 제어 방출성 펩티드 제형 | |
| JP7650074B2 (ja) | 眼疾患を治療するための組成物及び方法 | |
| AU2018329118B2 (en) | Pharmaceuticals and devices for the covalent immobilization to the extracellular matrix by transglutaminase | |
| Dahiya et al. | Ocular delivery of peptides and proteins | |
| Lee et al. | Implantable devices to treat ophthalmic conditions: drug delivery systems | |
| CN115715205B (zh) | 用于眼科用途的新型药物递送系统 | |
| US20240226241A1 (en) | Formulations for intraocular delivery of peptides derived from type iv collagen | |
| AU2019270488B2 (en) | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase | |
| Kim et al. | Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives. Pharmaceutics 2021, 13, 108 | |
| Hameed et al. | Controlled Release of Therapeutic Proteins | |
| Eskandari et al. | ÔØ Å ÒÙ× Ö ÔØ | |
| Rivers et al. | 10 Protein Drug Delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210507 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210507 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20210922 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210922 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211110 |